Hims & Hers Health (NYSE:HIMS) shares surged as much as 52% in early trading Monday after the telehealth leader announced a surprising end to its legal battle with Novo Nordisk.
Under a new strategic collaboration, Hims & Hers will pivot away from its controversial compounded semaglutide offerings to become an official distributor of Novo’s branded GLP-1 blockbusters, Wegovy and Ozempic, starting later this month.
The agreement marks a dramatic de-escalation of a month-long conflict.
In February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers, alleging that the platform’s sale of a $49 compounded weight-loss pill misled consumers and utilized inauthentic active ingredients.
As part of today’s settlement, Novo Nordisk has agreed to dismiss all pending litigation, while Hims & Hers has committed to removing all advertisements for compounded GLP-1 products from its platform.
The partnership will provide Hims & Hers customers with access to authentic, FDA-approved medications at Novo's self-pay prices, which have recently been adjusted to range between $149 and $299 per month to compete with off-brand alternatives.
HIMS stock hit an intraday high of $24.10, adding more than $1.7 billion to the company’s market capitalization in a single session.